Main menu

NEW YORK (GenomeWeb News) – DxS has received a license from Canadian regulatory authorities to sell its TheraScreen: K-RAS Mutation Kit as a companion diagnostic for Amgen's colorectal cancer therapy panitumumab (Vectibix), the UK-based firm said today.

In addition, Health Canada licensed the assay for broader use as a diagnostic for other anti-EGFR therapies beyond Vectibix.